A detailed history of Luminus Management LLC transactions in Lucid Diagnostics Inc. stock. As of the latest transaction made, Luminus Management LLC holds 1,152,915 shares of LUCD stock, worth $1.15 Million. This represents 0.56% of its overall portfolio holdings.

Number of Shares
1,152,915
Previous 725,825 58.84%
Holding current value
$1.15 Million
Previous $595,000 58.82%
% of portfolio
0.56%
Previous 0.4%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.75 - $0.88 $320,317 - $375,839
427,090 Added 58.84%
1,152,915 $945,000
Q2 2024

Aug 14, 2024

BUY
$0.67 - $1.04 $5,472 - $8,494
8,168 Added 1.14%
725,825 $595,000
Q1 2024

May 15, 2024

SELL
$0.81 - $1.52 $45,027 - $84,495
-55,589 Reduced 7.19%
717,657 $581,000
Q4 2023

Feb 15, 2024

SELL
$1.16 - $1.54 $118,150 - $156,855
-101,854 Reduced 11.64%
773,246 $1.09 Million
Q3 2023

Nov 14, 2023

SELL
$1.17 - $1.65 $3,835 - $5,408
-3,278 Reduced 0.37%
875,100 $1.02 Million
Q2 2023

Aug 14, 2023

BUY
$1.28 - $1.78 $29,539 - $41,078
23,078 Added 2.7%
878,378 $1.22 Million
Q1 2023

May 15, 2023

BUY
$1.17 - $1.77 $35,451 - $53,631
30,300 Added 3.67%
855,300 $1.2 Million
Q4 2022

Feb 14, 2023

SELL
$1.21 - $2.27 $26,211 - $49,172
-21,662 Reduced 2.56%
825,000 $1.12 Million
Q3 2022

Nov 14, 2022

SELL
$1.53 - $3.45 $41,527 - $93,639
-27,142 Reduced 3.11%
846,662 $1.3 Million
Q2 2022

Aug 15, 2022

BUY
$1.73 - $3.44 $204,697 - $407,027
118,322 Added 15.66%
873,804 $1.98 Million
Q1 2022

May 13, 2022

SELL
$2.85 - $5.24 $1.43 Million - $2.63 Million
-502,582 Reduced 39.95%
755,482 $2.54 Million
Q4 2021

Feb 15, 2022

BUY
$4.87 - $11.76 $6.13 Million - $14.8 Million
1,258,064 New
1,258,064 $6.76 Million

Others Institutions Holding LUCD

About Lucid Diagnostics Inc.


  • Ticker LUCD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 38,568,500
  • Market Cap $38.6M
  • Description
  • Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarc...
More about LUCD
Track This Portfolio

Track Luminus Management LLC Portfolio

Follow Luminus Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Luminus Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Luminus Management LLC with notifications on news.